High Arctic Announces Renewal of Normal Course Issuer Bid

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF U.S. SECURITIES LAW

CALGARY, Alberta, Dec. 08, 2020 (GLOBE NEWSWIRE) — High Arctic Energy Services Inc. (TSX: HWO) (“High Arctic” or the “Corporation”) is pleased to announce that it has made the necessary filings and received the necessary approvals to conduct a normal course issuer bid (“NCIB”) through the facilities of the Toronto Stock Exchange (“TSX”).

The TSX has accepted the Corporation’s notice to conduct the NCIB to purchase outstanding common shares on the open market, in accordance with the rules of the TSX. As approved by the TSX, the Corporation is authorized to purchase up to 2,437,983 common shares, representing approximately 5% of the issued and outstanding shares of High Arctic. There were 48,759,660 common shares outstanding as of November 30, 2020. The maximum number of common shares that High Arctic may purchase on any given day is 14,063 common shares, which represents 25% of the average daily trading volume of 56,255 common shares on the TSX for the six-month period ended November 30, 2020. High Arctic may also make one weekly block repurchase which exceeds the daily limit subject to prescribed rules. All common shares acquired under the NCIB will be cancelled.

The Corporation is authorized to make purchases during the period from December 11, 2020 to December 10, 2021, or until such earlier time as the NCIB is completed or terminated at the option of the Corporation. Any common shares the Corporation purchases under the NCIB will be purchased on the open market through the facilities of the TSX or alternative Canadian markets, at the prevailing market price at the time of the transaction. The Corporation has appointed an independent brokerage agent to conduct the NCIB transactions under an automatic purchase plan agreement (“APPA”) dated December 11, 2020. The APPA will allow the broker to purchase common shares under the bid during internal blackout periods when the Corporation would normally not be permitted to trade in its shares. Such purchases will be at the sole discretion of the broker based on direction received from High Arctic prior to any blackout period and in accordance with all regulatory and securities law.

The Corporation believes that from time to time the market price of the High Arctic common shares may not reflect their underlying value and that, at such times, the purchase of common shares for cancellation will increase the proportionate interest of, and be advantageous to, all remaining shareholders. In addition, the purchases by High Arctic under the NCIB may increase liquidity to the Corporation’s shareholders wishing to sell their common shares. The Corporation’s previous NCIB expired on December 1, 2020 and under that program, a total of 1,137,100 common shares at a weighted average price of $0.72 per share have been repurchased for cancellation.

About High Arctic

High Arctic is a publicly traded company listed on the Toronto Stock Exchange under the symbol “HWO”. The Corporation’s principal focus is to provide drilling and specialized well completion services, equipment rentals and other services to the oil and gas industry.

High Arctic is a market leader providing drilling and specialized well completion services and supplies rig matting, camps and drilling support equipment on a rental basis in Papua New Guinea.  The Canadian operations provide well servicing, well abandonment, snubbing and nitrogen services and equipment on a rental basis to a large number of oil and natural gas exploration and production companies operating in Western Canada and the United States. 

For more information, please contact:

Michael J. Maguire Christopher Ames
Chief Executive Officer VP Finance & Chief Financial Officer
Phone: 587-318-3826 Phone: 587-318-2218
info@haes.ca
 



RM LAW Announces Class Action Lawsuit Against Splunk Inc.

PR Newswire

BERWYN, Pa., Dec. 8, 2020 /PRNewswire/ — RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased Splunk Inc. (“Splunk” or the “Company”) (NASDAQ: SPLK) securities during the period from October 21, 2020 through December 2, 2020 inclusive (the “Class Period”).

Splunk shareholders may, no later than February 2, 2021 move the Court for appointment as a lead plaintiff of the Class. If you purchased shares of Splunk and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (844) 291-9299 or to sign up online, click here.

After the markets closed on December 2, 2020, Splunk stunned the market when it announced its financial results for the third quarter of 2021. These results fell short of annual recurring and total revenue estimates, and Splunk reported a loss of 7 cents per share versus an expected gain of 8 cents per share. Splunk’s forecast for the fourth quarter of 2020 was also lower than expected. Numerous analysts have already downgraded the stock and cut their price targets. This includes JPMorgan, who was “blindsided by the magnitude of too many large deals slipping in the final days of October on the heels of an upbeat analyst day 10 days prior to the quarter close,” on October 21, 2020, “at which the company reaffirmed guidance and stated that it was excited about near-term and long-term growth prospects.” Shares fell over 23% in one trading day from their December 2, 2020 closing price, representing billions of dollars in lost market capitalization.

If you are a member of the class, you may, no later than February 2, 2021 request that the Court appoint you as lead plaintiff of the class.  A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation.  In order to be appointed lead plaintiff, the Court must determine that the class member’s claim is typical of the claims of other class members, and that the class member will adequately represent the class.  Under certain circumstances, one or more class members may together serve as “lead plaintiff.”  Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff.  You may retain RM LAW, P.C. or other counsel of your choice, to serve as your counsel in this action.

For more information regarding this, please contact RM LAW, P.C.  (Richard A. Maniskas, Esquire) toll-free at (844) 291-9299 or by email at rm@maniskas.com or click here.   For more information about class action cases in general or to learn more about RM LAW, P.C. please visit our website by clicking here

RM LAW, P.C. is a national shareholder litigation firm.  RM LAW, P.C. is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.


CONTACT:



RM LAW, P.C.


Richard A. Maniskas, Esquire


1055 Westlakes Dr., Ste. 300


Berwyn, PA 19312


484-324-6800


844-291-9299



rm@maniskas.com

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/rm-law-announces-class-action-lawsuit-against-splunk-inc-301188882.html

SOURCE RM LAW, P.C.

Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

Takeda’s Pipeline Has Potential to Contribute Significantly to Revenue Growth Over Next Decade

  • Company Aiming for Mid-Single-Digit Revenue CAGR Over Next Decade Amounting to JPY5 Trillion ($47 Billion) by FY20301
  • Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies
  • Near-Term Late-Development Milestones Expected Across All Wave 1 Programs, Including Approval of a New Drug Application to U.S. Food and Drug Administration for TAK-721 in Eosinophilic Esophagitis, and Regulatory Filings for Dengue Vaccine in Endemic Countries and the EU
  • Company Provides New Peak Revenue Estimates for Global Brands Driving Growth Momentum in Mid-Term

OSAKA, Japan–(BUSINESS WIRE)–
As part of its Wave 1 Pipeline Market Opportunity Call, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) provided an update on its pipeline portfolio, which has the potential to contribute significantly to revenue growth for the company over the next decade. The company also shared its PTS adjusted2 view for FY2019-FY2030 revenue CAGR (low single-digit), as well as its goal for FY2019-FY2030 revenue CAGR (mid-single-digit), amounting to JPY5 trillion ($47 billion) by FY2030.3

The majority of this revenue growth is expected to come from the company’s Wave 1 pipeline, which includes 12 unique New Molecular Entities (NMEs), representing potential best-in-class/first-in-class therapies, and its existing 14 global brands. Of the Wave 1 programs, five have received Breakthrough Therapy designation and three were granted fast track designation by the U.S. Food and Drug Administration (FDA). In addition, one program received designation under the SAKIGAKE Designation System by the Japanese Ministry of Health, Labour and Welfare and another program was the first breakthrough designation granted by the China Food and Drug Administration to a multinational biopharmaceutical company.

“Our vision is to discover and deliver life-transforming treatments guided by our commitment to patients, our people and the planet,” said Christophe Weber, Takeda president and chief executive officer. “Our Wave 1 pipeline is reflective of the high bar we have set to focus solely on finding treatments, preventions and cures for targeted populations with high unmet medical needs, and bringing them to patients around the world.”

During the call, Takeda provided a deep dive into TAK-721, which has the potential to be the first FDA-approved agent for the treatment of eosinophilic esophagitis (EoE), and TAK-003, which is a live attenuated tetravalent vaccine for prevention of dengue disease. In addition, the company highlighted the sustained momentum of global brands such as Entyvio®, and the commercial capabilities that will help to ensure launch success.

Bringing a Highly Innovative Pipeline to Patients for Sustained Growth

Takeda has built a world-class, state-of-the-art R&D engine and has generated a diverse and dynamic pipeline of approximately 40 clinical-stage new molecular entities that is beginning to deliver. All 12 Wave 1 pipeline NMEs have anticipated near-term late-development milestones, pivotal data readouts or pivotal study starts. Takeda has expanded its global capabilities including data insights and analytics, patient services, and evidence generation to enhance commercial excellence for delivering these life-transforming therapies to patients around the world.

Beyond the Wave 1 pipeline, Takeda’s research engine, comprised of internal research capabilities and more than 200 active partnerships, is rapidly advancing a steady stream of next-generation therapies in Wave 2 of our pipeline that will provide sustained growth in FY2025 and beyond. These Wave 2 pipeline programs are designed to provide transformative or curative potential for targeted populations with high unmet need across core therapeutic areas. They are based on targets with strong human validation, represent diverse modalities and leverage new platform capabilities in cell therapy, gene therapy and data sciences.

ABOUT TAK-721 and TAK-003

TAK-721 (budesonide oral suspension)

Takeda’s TAK-721 is a mucoadherent, topical, viscous formulation of budesonide, formulated specifically as an investigational treatment for (EoE). If approved, TAK-721 will be the first FDA-approved treatment for EoE; Takeda plans to use the trade name Eohilia (budesonide oral suspension). To date, it has received both Breakthrough Therapy designation and Orphan Drug designation from the FDA. Its development program is the first and largest EoE Phase 3 clinical trial program in the U.S. to report results, and includes the pivotal Phase 3 trials ORBIT1 and ORBIT2 which investigated the safety and efficacy of TAK-721 in adolescent and adult patients (11 to 55 years of age) with EoE. Breakthrough Therapy designation and Orphan Drug designation do not guarantee approval or commercial availability.

TAK-003

Takeda’s tetravalent dengue vaccine candidate (TAK-003) has the potential to help address the massive global burden of dengue including key priorities for dengue control such as protection of seronegative individuals (persons not previously exposed to dengue) and prevention of hospitalization. TAK-003 is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four vaccine viruses. The TAK-003 development program includes the pivotal Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES), a double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of two doses of TAK-003 in the prevention of laboratory-confirmed symptomatic dengue fever of any severity and due to any of the four dengue virus serotypes in children and adolescents. The TIDES trial is continuing, and safety and efficacy will be assessed over a total of four and a half years. Dengue is the fastest spreading mosquito-borne viral disease and was recognized by WHO to be one of the top ten threats to global health in 2019.

To access a replay of today’s Wave 1 Pipeline Market Opportunity Call, including presentation slides with the latest data and updates on TAK-721 and TAK-003, visit https://www.takeda.com/investors/ir-events/.

Takeda plans to host part 2 of the Wave 1 pipeline update on April 6, 2021 (date subject to change). This will include a deep dive into TAK-925/994, maribavir and an update on oncology assets.

ABOUT TAKEDA PHARMACEUTICAL COMPANY LIMITED

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Takeda Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations; the success of or failure of product development programs; decisions of regulatory authorities and the timing thereof; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

Medical information

This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development.

_______________

1
Includes incremental revenues on a non-PTS (probability of technical success) basis (i.e., figures represent best case scenarios, including technical success that Takeda does not currently consider probable to occur and should not be seen as a forecast or target figure).

2 PTS (Probability of Technical Success) adjusted figures represent Takeda’s base case, i.e. its estimate of revenue based on technical milestones it believes it is probable to achieve.

3 Does not include any potential impacts imposed by the Most Favored Nation Model interim final rule issued by the U.S. Centers for Medicare & Medicaid Services (CMS) on November 20, 2020, which are currently being assessed.

Media:

Japanese Media

Kazumi Kobayashi

kazumi.kobayashi@takeda.com

+81 (0) 3-3278-2095

Media Outside Japan

Holly Campbell

holly.campbell@takeda.com

+1 617-588-9013

Investor Relations:

Atsushi Seki

Atsushi.seki@takeda.com

+81 (0) 3-3278-3684

KEYWORDS: Japan Asia Pacific

INDUSTRY KEYWORDS: Science Cardiology Biotechnology Research Pharmaceutical Health Infectious Diseases Clinical Trials

MEDIA:

Logo
Logo

CORRECTING and REPLACING Vivint Smart Home Announces Redemption of Public Warrants

CORRECTING and REPLACING Vivint Smart Home Announces Redemption of Public Warrants

PROVO, Utah–(BUSINESS WIRE)–
First paragraph, first sentence of release should read: …on January 7, 2021… (instead of …on January 7, 2020…). Tenth paragraph, third sentence of release should read: …as filed on November 5, 2020… (instead of …as filed on September 5, 2020…).

The updated release reads:

VIVINT SMART HOME ANNOUNCES REDEMPTION OF PUBLIC WARRANTS

Vivint Smart Home, Inc. (NYSE: VVNT) (the “Company”) today announced that it has delivered a notice of redemption to redeem all of its outstanding warrants (the “Public Warrants”) to purchase shares of the Company’s Class A common stock, $0.0001 par value per share (the “Common Stock”), that were issued under the Warrant Agreement, dated as of September 26, 2017 (the “Warrant Agreement”), by and between the Company (f/k/a Mosaic Acquisition Corp.) and Continental Stock Transfer & Trust Company, as warrant agent (the “Warrant Agent”), and that remain unexercised at 5:00 p.m., New York City time, on January 7, 2021 (the “Redemption Date”) for a redemption price of $0.01 per Public Warrant (the “Redemption Price”). Warrants to purchase Common Stock that were issued under the Warrant Agreement in a private placement and still held by the initial holders thereof or their permitted transferees are not subject to this redemption.

Under the terms of the Warrant Agreement, the Company has the right to redeem all of the outstanding Public Warrants if the last sales price of the Common Stock is at least $18.00 per share on each of 20 trading days within any 30-day trading period ending on the third business day prior to the date on which a notice of redemption is given. The last sales price of the Common Stock has been at least $18.00 per share on each of 20 trading days within the 30-day trading period ending on December 3, 2020. At the direction of the Company, the Warrant Agent has delivered a notice of redemption to each registered holder of the outstanding Public Warrants.

The Public Warrants may be exercised by the holders thereof until 5:00 p.m. New York City time on the Redemption Date to purchase fully paid and non-assessable shares of Common Stock underlying such warrants, at the exercise price of $11.50 per share. Any Public Warrants that remain unexercised at 5:00 p.m. New York City time on the Redemption Date will be void and no longer exercisable, and the holders of those Public Warrants will be entitled to receive only the redemption price of $0.01 per warrant.

None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Public Warrants as to whether to exercise or refrain from exercising any Public Warrants.

The shares of Common Stock underlying the Public Warrants have been registered by the Company under the Securities Act of 1933, as amended, and are covered by a registration statement filed on Form S-1 with, and declared effective by, the Securities and Exchange Commission (Registration No. 333-236340).

Questions concerning redemption and exercise of the Public Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000.

No Offer or Solicitation

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any offer of any of the Company’s securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About the Company

Vivint is a leading smart home company in North America. Vivint delivers an integrated smart home system with in-home consultation, professional installation and support delivered by its Smart Home Pros, as well as 24/7 customer care and monitoring. Dedicated to redefining the home experience with intelligent products and services, Vivint serves approximately 1.7 million customers throughout the U.S. and Canada. For more information, visit https://www.vivint.com.

Forward Looking Statements

This press release includes certain forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These statements are based on the beliefs and assumptions of the Company’s management. Although the Company believes that its plans, intentions and expectations reflected in or suggested by these forward-looking statements are reasonable, the Company cannot assure you that it will achieve or realize these plans, intentions or expectations. Forward-looking statements are inherently subject to risks, uncertainties and assumptions. Generally, statements that are not historical facts, including statements concerning our possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. These statements may be preceded by, followed by or include the words “believes,” “estimates,” “expects,” “projects,” “forecasts,” “may,” “will,” “should,” “seeks,” “plans,” “scheduled,” “anticipates” or “intends” or similar expressions.

Forward-looking statements are not guarantees of performance. You should not put undue reliance on these statements which speak only as of the date hereof. You should understand that the factors discussed in our Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020, as filed on May 11, 2020, our Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2020, as filed on August 6, 2020 and our Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2020, as filed on November 5, 2020, as such factors may be updated from time to time in the Company’s periodic filings with the SEC, could affect our future results and could cause those results or other outcomes to differ materially from those expressed or implied in our forward-looking statements.

The Company undertakes no obligations to update or revise publicly any forward-looking statements, whether a result of new information, future events, or otherwise, except as required by law.

Source: Vivint Smart Home, Inc.

VVNT-N

Investor Relations Contact:

Nate Stubbs

VP, Investor Relations

ir@vivint.com

KEYWORDS: United States North America Utah

INDUSTRY KEYWORDS: Technology Mobile/Wireless Construction & Property Security Audio/Video Hardware Electronic Design Automation Residential Building & Real Estate Consumer Electronics

MEDIA:

Logo
Logo

Seven Leading Non-Profit Providers Leverage Experience Treating Patients with Advanced Illness at Home for New, Unique Medicare Care Model

New Medicare Program Aligns Incentives to Provide Comprehensive Care to High-Needs Patients

Falls Church, Virginia, Dec. 08, 2020 (GLOBE NEWSWIRE) — Seven of the nation’s largest and well-known non-profit advanced illness providers have formed Advanced Illness Partners (AIP) to participate in a new model of care from the Center for Medicare and Medicaid Innovation (CMMI). One of CMMI’s most prominent new models, Direct Contracting allows organizations to accept financial risk and make use of new flexibilities and quality improvement incentives to better serve Medicare beneficiaries with complex and chronic illness.

Advanced Illness Partners is among 51 entities nationwide designated by CMMI to participate in this new program. Organizations participating in the Model are committed to providing high-value, comprehensive care to high-need Medicare beneficiaries— and are willing to accept risk for the most complex patients in the U.S. healthcare system.

AIP is comprised of seven organizations from six states—Arizona, Florida, Washington D.C., Virginia, Ohio, Nevada and Oregon—which have a combined nearly 250 years of experience in caring for those with advanced chronic illness through largely home-based, community-oriented care. The partners currently serve over 60,000 Medicare beneficiaries annually and have prior success in value-based models such as Independence at Home (IAH), Program for All-Inclusive Care for the Elderly (PACE), and the Medicare Care Choices Model (MCCM).

AIP organizations have provided home-based care in a cost-efficient manner for many years. Now, in light of the COVID-19 pandemic and the consistently stated preferences of many seniors to “age in place,” AIP is excited to show just how effective this model of care can be in meeting patients’ needs.

Eric De Jonge M.D. is a Nationally Recognized Geriatrician and CMO for AIP

Dr. Eric De Jonge, Director of Geriatrics at Capital Caring Health and Chief Medical Officer for Advanced Illness Partners shared, “We’re excited to participate in CMMI’s innovative program to bring advanced illness care upstream and serve patients with complex, chronic disease in the home setting for the long-term. As non-profit providers, our network allows us to remain community-based while also sharing best practices and economies to scale to invest in tools that help us improve care and lower costs of care for high-needs patients.”

The Advanced Illness Partners include Pure Healthcare, a program from Ohio’s Hospice; Geriatric Solutions, a program of the Hospice of the Valley in Arizona; Hope Healthcare in Fort Myers, Florida; Housecall Providers, a part of the CareOregon family; Cornerstone Hospice in Central Florida; Nathan Adelson Hospice in Las Vegas, Nevada and Capital Caring Health in D.C., Maryland and Virginia. All seven organizations are excited to learn from each other and share best practices in treating patients.

Medicare beneficiaries looking for coordinated and comprehensive care may seek to enroll in the new program by visiting AdvancedIllnessPartners.org.

For more information on Advanced Illness Partners or the collaboration please contact Capital Caring Health’s Director of Population Health, Jacqueline Kimmell, at jkimmell@capitalcaring.org.

The statements contained in this document are solely those of the authors and do not necessarily reflect the views or policies of CMS. The authors assume responsibility for the accuracy and completeness of the information contained in this document.

Attachment



Nancy Cook
Capital Caring Health
ncook@capitalcaring.org

Whitecap And TORC Announce Strategic Combination Creating a Leading Sustainable Light Oil Focused Company with a Significantly Enhanced Free Funds Flow Profile Supporting a 6% Dividend Increase

Canada NewsWire

CALGARY, AB, Dec. 8, 2020 /CNW/ – Whitecap Resources Inc. (“Whitecap” or the “Company”) (TSX: WCP) and TORC Oil & Gas Ltd. (“TORC”) (TSX: TOG) are pleased to announce a business combination (the “Business Combination”) of two strong energy franchises resulting in a well-capitalized, low decline, light oil weighted company with an attractive free funds flow profile.

Whitecap and TORC have entered into a business combination agreement (the “Agreement”) under which the companies have agreed to combine their businesses in an at market, all-stock transaction valued at approximately $900 million, including TORC’s net debt, estimated at $335 million as of December 31, 2020. Under the terms of the Agreement, shareholders of TORC (“TORC Shareholders”) will receive 0.57 Whitecap common shares (the “Whitecap Shares”) in exchange for each TORC common share held (the “TORC Shares”). The at market exchange ratio was determined using ten-day volume weighted average share prices of the Whitecap Shares and the TORC Shares on the Toronto Stock Exchange (“TSX”) prior to the signing of the Agreement.

The combined entity will be stewarded by the existing Whitecap executive team and will continue to advance a total return model combining modest production growth with meaningful cash dividends. The Business Combination has been unanimously approved by the Boards of Directors of both Whitecap and TORC and is expected to close on or before February 25, 2021, subject to customary conditions, including the receipt of necessary regulatory and shareholder approvals.

Strategic and Financial Benefits of the Business Combination

  • Material Size and Scale. Significantly increases Whitecap’s scale and core area dominance as TORC’s asset base fits directly into Whitecap’s current core areas creating one of the largest pure play conventional light oil producers in Canada with over 100,000 boe/d (78% oil and NGLs) of corporate production. The combined entity will have an enterprise value of approximately $4 billion and has paid $1.4 billion in cumulative dividends to shareholders since inception.

  • Improved Free Funds Flow Profile. TORC’s current production is approximately 25,000 boe/d and its production in 2021 is expected to average 22,000 boe/d due to a moderated capital program resulting in a production decline rate of less than 19%. The lower production profile is designed to enhance the combined entity’s ability to generate significant free funds flow to increase cash returns to shareholders. The combined entity is expected to have over $300 million of free funds flow supported by a base production decline rate of approximately 17%.

  • Enhanced Long-Term Shareholder Returns. Return of capital to shareholders continues to be a priority for Whitecap and is an important component of its total return strategy. The combined entity will be able to generate significantly more free funds flow which supports a 6% increase to the monthly dividend from $0.01425 per share to $0.01508 per share ($0.18096 per share annualized). The dividend increase is expected to be effective with the March 2021 dividend payable in April 2021. The pro forma 2021 total payout ratio is expected to be 66% at a crude oil price of US$45/bbl WTI.

  • Significant Synergies. Tangible cost savings and inventory optimization opportunities are expected to result in incremental free funds flow of approximately $15 million in year one from corporate and operational synergies in the near term.

  • Top Tier Balance Sheet. The combined business will maintain its strong credit profile and will have ample liquidity to manage commodity price volatility. Whitecap’s credit facilities are covenant based and are not subject to yearly credit determinations. The combined business is expected to benefit from approximately $6 million in lower interest expense and is expected to reduce net debt by over $200 million in 2021, resulting in a pro forma debt to EBITDA ratio of 1.8x at US$45/bbl WTI.

  • Sustainable Development. Whitecap remains committed to best-in-class environment, social and governance (“ESG”) practices and continuously improving its ESG profile. Whitecap is the operator of the Weyburn Unit, one of the largest carbon capture and utilization storage projects in the world, currently sequestering more than 2 million tonnes of CO2 annually and providing the Company with its net negative emitter status.

  • Disciplined Leadership and Governance. The combined business will continue to be led by the Whitecap executive team and Board of Directors. Pursuant to the Agreement and subject to receipt of approval by the shareholders of Whitecap (“Whitecap Shareholders”) of the resolution to amend the articles of Whitecap (the “Article Amendment Resolution”) at the Whitecap Meeting (as defined below), Whitecap has agreed to appoint a designated director from TORC to its Board of Directors on closing.

Market Leading Light Oil Player

The strategic business combination of Whitecap and TORC creates a leading oil weighted producer in Western Canada with a focused asset base exhibiting lower production declines, high operating netbacks and strong capital efficiencies.

Grant Fagerheim, Whitecap’s President & CEO, stated: “We are combining two strong Canadian energy producers to form a leading large-cap, light oil company geared towards generating sustainable long-term returns for shareholders while prioritizing responsible Canadian energy development. Despite the challenging conditions and significant volatility throughout the year, we have become an even stronger and more resilient energy producer entering 2021 with the combination with TORC as well as the NAL transaction announced on August 31, 2020. We would like to thank our employees for their continued exemplary efforts and our shareholders for their ongoing support. We look forward to advancing returns to our shareholders into the future.”

There is significant overlap in Whitecap’s and TORC’s asset bases providing for meaningful operational synergies and inventory optimization opportunities. The combined business will have 67% of its production under waterflood recovery, supporting its industry leading base production decline rate of 17%.

Brett Herman, TORC’s President & CEO, stated, “On behalf of TORC’s management and Board of Directors, we would like to thank our shareholders for their ongoing support over the past ten years. We believe our corporate values are closely aligned with Whitecap’s management team and the announced business combination will create an exceptionally resilient energy producer that is positioned for growth, while delivering a sustainable dividend to shareholders. In a market environment that is increasingly favouring size and scale, a business combination with Whitecap exposes TORC shareholders to a larger platform while remaining consistent with our existing philosophy of balancing growth with financial discipline along with prudent capital allocation.  We are pleased to become shareholders of Whitecap.”

Canada Pension Plan Investment Board (“CPP Investments”) has been a TORC shareholder since 2013 and has entered into a Support Agreement whereby it will vote in favour of the transaction under the terms of the agreement.

“As a long-standing investor in TORC, we’re pleased to support this transaction, which has compelling economic merits for both companies and builds a stronger business of scale that can continue to participate in industry consolidation. We would also like to thank TORC’s management team and the Board for their work in building a strong energy franchise,” says Michael Koen, Managing Director, Head of Relationship Investments, CPP Investments.

Preliminary Pro Forma 2021 Outlook

Following the Business Combination, Whitecap remains well positioned to continue to advance internal development opportunities and selectively consolidate high-quality assets. Whitecap’s competitive advantages include a strong balance sheet, high funds flow netback assets, shallow production decline profile and depth and quality of inventory to support Whitecap’s fully funded model. Whitecap remains committed to growing its business over the long-term in combination with providing Whitecap Shareholders with meaningful cash returns.

Whitecap’s stand-alone forecasted base case for 2021 (including the completion of the NAL Transaction, as defined below), is average production of 81,000 – 83,000 boe/d on capital investments of $250$270 million as press released on October 29, 2020. The pro forma entity is expected to have average production in 2021 of 99,000 – 101,000 boe/d (assuming a closing date of February 25, 2021) on capital investments of $280 to $300 million. Based on this spending and production profile, Whitecap anticipates generating funds flow of approximately $602 million with free funds flow of approximately $312 million and a total payout ratio of 66% based on commodity prices of US$45/bbl WTI and C$2.50/GJ AECO. A detailed 2021 budget will be provided on close of the Business Combination.

NAL Update

On August 31, 2020, Whitecap announced that it had entered into an agreement in an all-stock transaction valued at approximately $155 million with NAL Resources Limited and a privately held wholly owned subsidiary of Manulife Financial Corporation (the “NAL Transaction”). With integration progressing, Whitecap continues to anticipate the close of the NAL Transaction on January 4, 2021.

Recommendations of the Whitecap and TORC Board of Directors

The Whitecap Board of Directors has unanimously determined that the Business Combination and the execution of the Agreement is in the best interests of Whitecap, that the consideration to be paid by Whitecap pursuant to the Business Combination is fair, from a financial point of view, to Whitecap and has unanimously recommended that the Whitecap Shareholders vote in favour of the resolution approving the issuance of the Whitecap Shares pursuant to the Business Combination (the “Issuance Resolution”) at the Whitecap Meeting. National Bank Financial Inc. has provided the Whitecap Board with a fairness opinion stating that, as of the date thereof and subject to the assumptions, limitations, and qualifications set forth therein, the consideration to be paid to the TORC Shareholders is fair, from a financial point of view, to Whitecap. All of the directors and officers of Whitecap have entered into agreements with TORC pursuant to which they have agreed to vote their Whitecap Shares in favour of the Issuance Resolution and the Article Amendment Resolution and otherwise support the Business Combination.

The TORC Board of Directors has unanimously determined that the Business Combination and the execution of the Agreement is in the best interests of TORC, that the Business Combination is fair to TORC Shareholders and has unanimously recommended that the TORC Shareholders vote in favour of the resolution approving the Business Combination (the “Business Combination Resolution”) at the TORC Meeting (as defined below). RBC Capital Markets has provided an opinion to the Board of Directors of TORC that, as of the date thereof and subject to the assumptions, limitations and qualifications set forth therein, the consideration to be received under the Transaction is fair from a financial point of view to the holders of the TORC Shares. TORC’s management team and Board of Directors (“TORC Insiders”) and CPP Investments have all entered into support agreements with Whitecap and have agreed to vote their TORC Shares in favour of the Business Combination Resolution and otherwise support the Business Combination.

Combination Structure Details

Whitecap and TORC have entered into the Agreement to effect the Business Combination through a plan of arrangement under the Business Corporations Act (Alberta). Under the terms of the Business Combination, Whitecap will acquire all of the issued and outstanding shares of TORC for share consideration. TORC Shareholders will receive 0.57 Whitecap Shares for each TORC Share owned. The exchange ratio was determined based on the volume weighted average trading price of the Whitecap Shares and TORC Shares on the TSX for the preceding ten trading days prior to the signing of the Agreement. As part of the Agreement, Whitecap will assume TORC’s net debt of $335 million estimated as at December 31, 2020.

TORC Insiders have agreed to enter into hold period agreements (“Hold Period Agreements”) with Whitecap on the completion of the Business Combination. The Hold Period Agreements will provide that, subject to certain exceptions, the TORC Insiders will not be entitled to transfer or otherwise dispose of the Whitecap Shares they acquire pursuant to the Business Combination for periods of three (3), six (6) and nine (9) months from the closing date of the Business Combination; one-third of the Whitecap Shares held by the TORC Insiders to be released after each period.

The Business Combination requires approval by at least 66⅔% of the votes cast by TORC Shareholders present in person or represented by proxy at a special meeting of TORC Shareholders to be called to consider the Business Combination (the “TORC Meeting”) and a majority of the votes cast by TORC Shareholders after excluding the votes cast by those persons whose votes may not be included under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions.

The issuance of the Whitecap Shares pursuant to the Business Combination requires approval by at least 50% of the votes cast by Whitecap Shareholders represented in person or by proxy at a special meeting of Whitecap Shareholders (the “Whitecap Meeting”) to be called to consider the Issuance Resolution, as required by the rules of the TSX. In addition, Whitecap Shareholders will be asked to consider the Article Amendment Resolution to increase its maximum number of directors so that Whitecap can appoint a designated director from the TORC Board of Directors to the Whitecap Board of Directors on closing.

The Agreement contemplates that the Whitecap Meeting and TORC Meeting will be held in February 2021. It is expected that a joint management information circular will be sent to the shareholders of each of Whitecap and TORC in January 2021. Closing of the Business Combination is expected to occur on or before February 25, 2021.

The Agreement provides for non-solicitation covenants on behalf of TORC which are subject to the fiduciary duty obligations of the TORC Board and provides Whitecap with the right to match any superior proposal received by TORC. The Agreement also provides for mutual non-completion fees of $20 million in the event the Business Combination is not completed or is terminated by either party in certain circumstances.

The Agreement provides that completion of the Business Combination is subject to certain conditions, including the receipt of all required regulatory approvals, the approval of the TSX, the approval of the shareholders of Whitecap and TORC (as described above), the approval of the Court of Queen’s Bench of Alberta and approval under the Competition Act (Canada).

Advisors

National Bank Financial Inc. acted as exclusive financial advisor to Whitecap. Burnet, Duckworth & Palmer LLP is acting as Whitecap’s legal advisor.

RBC Capital Markets acted as exclusive financial advisor to TORC. McCarthy Tétrault LLP is acting as TORC’s legal advisor.

Conference Call and Webcast

Whitecap has scheduled a conference call and webcast to begin promptly at 10:00 am MT (12:00 noon ET) on December 9, 2020.

The conference call dial-in number is: 1-888-390-0605 or (587) 880-2175 or (416) 764-8609

A live webcast of the conference call will be accessible on Whitecap’s website at www.wcap.ca by selecting “Investors”, then “Presentations & Events”. Shortly after the live webcast, an archived version will be available for approximately 14 days.

Note Regarding Forward-Looking Statements

This press release contains forward-looking statements and forward-looking information (collectively “forward-looking information”) within the meaning of applicable securities laws relating to Whitecap and TORC’s current expectations, estimates, projections and assumptions, as applicable, that were made by each company in light of information available at the time the statement was made. Forward-looking information typically uses words such as “anticipate”, “believe”, “continue”, “trend”, “sustain”, “project”, “expect”, “forecast”, “budget”, “goal”, “guidance”, “plan”, “objective”, “strategy”, “target”, “intend”, “estimate”, “potential”, or similar words suggesting future outcomes, statements that actions, events or conditions “may”, “would”, “could” or “will” be taken or occur in the future, including statements about strategy, plans, focus, objectives, priorities and position; and the strategic rationale for, and anticipated benefits to be derived from, the Business Combination. In particular, and without limiting the generality of the foregoing, this press release contains forward-looking statements with respect to: TORC’s net debt estimated at $335 million as of December 31, 2020; Whitecap’s ability continue to advance a total return model combining modest production growth with meaningful cash dividends; the management team of the combined entity; that the Business Combination is expected to close on or before February 25, 2021; average 2021 production, production mix and production decline rate; the anticipated benefits of the Business Combination, including: (i) that the Business Combination will create the largest pure play conventional light oil producer in Canada with an enterprise value of approximately $4 billion, (ii) that the Business Combination will result in tangible cost savings and inventory optimization opportunities the anticipated benefits to be derived therefrom, (iii) TORC’s anticipated 2021 production and decline rates, (iv) that the combined entity is expected to have over $300 million of free fund flow; (v) that the Business Combination will result in a combined entity that is able to generate significantly more free funds flow and the anticipated benefits to be derived therefrom, (vi) the ability of the combined entity to generate significantly more free funds flow which will support an increase to Whitecap’s dividend of 6% and the timing of the payment, (vii) that the Business Combination will result in the combined entity having a total payout ratio of 66% at US$45/bbl WTI, (vii) that the Business Combination will result in lower interest expense, reduce net debt and the anticipated benefits therefrom, and (ix) that the Business Combination will result in lower production declines, high operating netbacks and strong capital efficiencies; the appointment of a TORC designee to the Whitecap Board of Directors on closing of the Business Combination; the execution of the Hold Period Agreements with TORC Insiders on closing of the Business Combination and the terms and conditions thereof; the timing of Whitecap Meeting and TORC Meeting; Whitecap’s competitive advantages include a strong balance sheet, high funds flow netback assets, shallow production decline rate and depth and quality of inventory to support Whitecap’s fully funded model; timing of closing of the NAL Transaction; Whitecap’s ability to grow its business for the long-term in combination with providing Whitecap Shareholders with meaningful cash dividends; 2021 average production and capital investments of the combined entity; and 2021 funds flow and free funds flow.

The forward-looking information is based on certain key expectations and assumptions made by each company, as applicable, including expectations and assumptions concerning prevailing commodity prices, exchange rates, interest rates, applicable royalty rates and tax laws; the impact (and the duration thereof) that the COVID-19 pandemic will have on (i) the demand for crude oil, NGLs and natural gas, (ii) Whitecap’s supply chain, including its ability to obtain the equipment and services it requires, and (iii) Whitecap’s ability to produce, transport and/or sell its crude oil, NGLs and natural gas; the ability of OPEC+ nations and other major producers of crude oil to reduce crude oil production and thereby arrest and reverse the steep decline in world crude oil prices; future production rates and estimates of operating costs; performance of existing and future wells; reserve volumes; anticipated timing and results of capital expenditures; the success obtained in drilling new wells; the sufficiency of budgeted capital expenditures in carrying out planned activities; the timing, location and extent of future drilling operations; the state of the economy and the exploration and production business; results of operations; performance; business prospects and opportunities; the availability and cost of financing, labour and services; the impact of increasing competition; ability to efficiently integrate assets and employees acquired through acquisitions, ability to market oil and natural gas successfully; access to capital; the timing of the completion of the Business Combination and receipt of applicable regulatory approvals and on the terms contemplated; and the closing of the NAL Transaction on the timing and terms and conditions currently contemplated.

Although the expectations and assumptions on which such forward-looking information is based are believed to be reasonable, undue reliance should not be placed on the forward-looking information because no assurance can be given that they will prove to be correct. Since forward-looking information addresses future events and conditions, by its very nature they involve inherent risks and uncertainties. These include, but are not limited to: the risks associated with the oil and gas industry in general such as operational risks in development, exploration and production; pandemics and epidemics; delays or changes in plans with respect to exploration or development projects or capital expenditures; the uncertainty of estimates and projections relating to reserves, production, costs and expenses; health, safety and environmental risks; commodity price and exchange rate fluctuations; interest rate fluctuations; marketing and transportation; loss of markets; environmental risks; competition; incorrect assessment of the value of acquisitions; failure to complete or realize the anticipated benefits of acquisitions or dispositions; ability to access sufficient capital from internal and external sources; failure to obtain required regulatory and other approvals; reliance on third parties and pipeline systems; and changes in legislation, including but not limited to tax laws, production curtailment, royalties and environmental regulations. Actual results, performance or achievement could differ materially from those expressed in, or implied by, the forward-looking information and, accordingly, no assurance can be given that any of the events anticipated by the forward-looking information will transpire or occur, or if any of them do so, what benefits that we will derive therefrom. The above summary of assumptions and risks related to forward-looking information has been included in this press release in order to provide security holders with a more complete perspective on future operations and such information may not be appropriate for other purposes.

Unless specifically indicated, all forward-looking information with respect to the combined entity assumes the completion of the NAL Transaction on the terms and conditions previously publicly announced by Whitecap.

Readers are cautioned that the foregoing lists of factors are not exhaustive. Additional information on these and other factors that could affect our operations or financial results are included in reports on file with applicable securities regulatory authorities and may be accessed through the SEDAR website (www.sedar.com).

These forward-looking statements are made as of the date of this press release and we disclaim any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

This press release contains future-oriented financial information and financial outlook information (collectively, “FOFI”) about Whitecap’s pro forma expected incremental funds flow, dividends, free funds flow, total payout ratio, lower interest expense, reduction in debt, debt to EBITDA, capital investments, funds flow and free funds flow, all of which are subject to the same assumptions, risk factors, limitations, and qualifications as set forth in the above paragraphs. The actual results of operations of Whitecap and the resulting financial results will likely vary from the amounts set forth in this presentation and such variation may be material. Whitecap and its management believe that the FOFI has been prepared on a reasonable basis, reflecting management’s best estimates and judgments. However, because this information is subjective and subject to numerous risks, it should not be relied on as necessarily indicative of future results. Except as required by applicable securities laws, Whitecap undertakes no obligation to update such FOFI. FOFI contained in this press release was made as of the date of this press release and was provided for the purpose of providing further information about Whitecap’s anticipated future business operations. Readers are cautioned that the FOFI contained in this press release should not be used for purposes other than for which it is disclosed herein.

Oil and Gas Advisories

“Boe” means barrel of oil equivalent based on 6 mcf of natural gas to 1 bbl of oil. Boe may be misleading, particularly if used in isolation. A boe conversion ratio of 6:1 is based on an energy equivalency conversion method primarily applicable at the burner tip and does not represent a value equivalency at the wellhead. In addition, given that the value ratio based on the current price of crude oil as compared to natural gas is significantly different from the energy equivalency of 6:1, utilizing a conversion on a 6:1 basis may be misleading as an indication of value.

Production

References to crude oil or natural gas production in this press release refer to the light and medium crude oil and conventional natural gas, respectively, product types as defined in National Instrument 51-101, Standards of Disclosure for Oil and Gas Activities.

Disclosure of production on a per boe basis in this press release consists of the constituent product types and their respective quantities as disclosed in the following table:

Crude oil

(bbls/d)

NGLs

(bbls/d)

Natural gas

(Mcf/d)

Total

(boe/d)

TORC Current

21,382

912

16,233

25,000

TORC 2021 Standalone

18,816

803

14,285

22,000

Whitecap 2021 Standalone (1)

53,250 – 54,798

8,203 – 8,334

 117,282 – 119,208

81,000 – 83,000

Whitecap 2021 Proforma

68,645 – 70,193

8,860 – 8,991

128,970 – 130,896

99,000 – 101,000

Note:


(1) Includes NAL Transaction

Non-GAAP Measures

This press release includes non-GAAP measures as further described herein. These non-GAAP measures do not have a standardized meaning prescribed by International Financial Reporting Standards (“IFRS” or, alternatively, “GAAP”) and, therefore, may not be comparable with the calculation of similar measures by other companies.

“Enterprise value” is calculated as market capitalization plus net debt. Management believes that enterprise value provides a useful measure of the market value of Whitecap’s debt and equity.

“Free funds flow” represents funds flow less expenditures on property, plant and equipment (“PP&E”). Management believes that free funds flow provides a useful measure of Whitecap’s ability to increase returns to shareholders and to grow the Company’s business. Previously, Whitecap also deducted dividends paid or declared in the calculation of free funds flow. The Company believes the change in presentation better allows comparison with both dividend paying and non-dividend paying peers.

“Market capitalization” is calculated as period end share price multiplied by the number of shares outstanding at the end of the period. Management believes that market capitalization provides a useful measure of the market value of Whitecap’s equity.

“Total payout ratio” is calculated as dividends paid or declared plus expenditures on PP&E, divided by funds flow. Management believes that total payout ratio provides a useful measure of Whitecap’s capital reinvestment and dividend policy, as a percentage of the amount of funds flow.

SOURCE Whitecap Resources Inc.

FICO Announces DOJ Antitrust Investigation Closed

PR Newswire

SAN JOSE, Calif., Dec. 8, 2020 /PRNewswire/ —

On March 15, 2020, FICO issued a statement in response to an official notification that the U.S. Department of Justice, Antitrust Division, had opened a civil investigation into potential exclusionary conduct by FICO. 

Earlier today, the Department of Justice informed FICO that it has closed that investigation. As a result, no enforcement action is being taken.

About FICO
FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956 and based in Silicon Valley, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 195 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 100 countries do everything from protecting 2.6 billion payment cards from fraud, to helping people get credit, to ensuring that millions of airplanes and rental cars are in the right place at the right time.

Learn more at http://www.fico.com

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/fico-announces-doj-antitrust-investigation-closed-301188930.html

SOURCE FICO

Antengene Announces Collaboration with Applied BioMath, LLC for Systems Pharmacology Modeling in Oncology

PR Newswire

SHANGHAI and HONG KONG, Dec. 8, 2020 /PRNewswire/ — Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced a collaboration with Applied BioMath, LLC for the development of systems pharmacology modeling in immuno-oncology. This collaboration aims to predict clinical starting and efficacious doses of ATG-101, a PD-L1/4-1BB bispecific antibody, for its first-in-human studies.

“We are pleased to establish a strategic collaboration with Applied BioMath and believe it will provide assistance and efficiency to our early clinical programs. We are very excited about the upcoming IND filing and first-in-human study of our lead program in our proprietary discovery pipeline, ATG-101. We believe that with the collaboration of Applied BioMath, the transition from discovery to clinical development will be more efficient and we will be able to accelerate dose escalation of the clinical program,” said Dr. Jay Mei, M.D., Ph.D., Founder, Chairman and CEO of Antengene.

“Predicting starting and efficacious doses for first-in-human studies is non-trivial for complex therapeutics such as Antengene’s bispecific therapeutic,” said Dr. John Burke, Ph.D., Co-Founder, President, and CEO of Applied BioMath. “We have developed algorithms and tools specifically for this purpose that have a proven track record of predicting such doses. We are looking forward to collaborating with Antengene and supporting them in this project.”

“Antengene is dedicated to developing first-in-class and/or best-in-class therapies in oncology and hematology,” said Dirk Hoenemann, M.D., VP and Head of Early Development and Asia Pacific Medical Affairs. “We decided to collaborate with Applied BioMath in an effort to provide ourselves a more accurate prediction of the starting and biologically optimal doses of ATG-101 in human, which is a critical part of our Phase I study.”

Antengene has previously entered into a partnership with Wuxi Biologics for CMC and Manufacturing of the asset (ATG-101). Through the collaboration, Antengene will leverage the outputs from mathematical modeling and simulation by Applied BioMath to further optimize and accelerate the development of ATG-101. 

About Antengene

Antengene Corporation Limited (“Antengene”, SEHK: 6996.HK) is a leading clinical-stage Asia-Pacific-based biopharmaceutical company that focused on innovative oncology medicines. Antengene aims to provide the most advanced anti-cancer drugs to patients in China, the Asia Pacific Region and around the world. Since its establishment, Antengene has built a pipeline of 12 clinical and pre-clinical stage assets, obtained 10 investigational new drug approvals and has 9 ongoing cross-regional clinical trials in Asia Pacific. The vision of Antengene is to “Treat Patients Beyond Borders”. Antengene aims to address significant unmet medical needs by discovering, developing and commercializing first-in-class/best-in-class therapeutics. For more information, please visit www.antengene.com.  

About Applied BioMath

Founded in 2013, Applied BioMath’s mission is to revolutionize drug invention. Applied BioMath uses mathematical modeling and simulation to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk drug research and development. Their approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through clinical trials. The Applied BioMath team leverages their decades of expertise in biology, mathematical modeling and analysis, high-performance computing, and industry experience to help groups better understand their candidate, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic. For more information about Applied BioMath and its services, visit www.appliedbiomath.com.

Forward-looking statements

The forward-looking statements made in this article relate only to the events or information as of the date on which the statements are made in this article. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. In this article, statements of, or references to, our intentions or those of any of our Directors or our Company are made as of the date of this article. Any of these intentions may alter in light of future development.

 

Cision View original content:http://www.prnewswire.com/news-releases/antengene-announces-collaboration-with-applied-biomath-llc-for-systems-pharmacology-modeling-in-oncology-301188049.html

SOURCE Antengene Corporation Limited

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Loop Industries, Inc. and Encourages Investors to Contact the Firm

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Loop Industries, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Loop Industries, Inc. (NASDAQ: LOOP) securities between September 24, 2018 and October 12, 2020 (the “Class Period”). Investors have until December 14, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

On October 13, 2020, Hindenburg Research published a report alleging, among other things, that “Loop’s scientists, under pressure from CEO Daniel Solomita, were tacitly encouraged to lie about the results of the company’s process internally.” The report also stated that “Loop’s previous claims of breaking PET down to its base chemicals at a recovery rate of 100% were ‘technically and industrially impossible,’” according to a former employee. Moreover, the report alleged that “Executives from a division of key partner Thyssenkrupp, who Loop entered into a ‘global alliance agreement’ with in December 2018, told us their partnership is on ‘indefinite’ hold and that Loop ‘underestimated’ both costs and complexities of its process.”

On this news, the Company’s share price fell $3.78, or over 32%, to close at $7.83 per share on October 13, 2020.

The complaint, filed on October 13, 2020, alleges that throughout the Class Period defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, defendants failed to disclose to investors: (1) that Loop scientists were encouraged to misrepresent the results of Loop’s purportedly proprietary process; (2) that Loop did not have the technology to break PET down to its base chemicals at a recovery rate of 100%; (3) that, as a result, the Company was unlikely to realize the purported benefits of Loop’s announced partnerships with Indorama and Thyssenkrupp; and (4) that, as a result of the foregoing, defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

If you purchased Loop securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Reata Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm

NEW YORK–(BUSINESS WIRE)–
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Eastern District of Texas on behalf of investors that purchased Reata Pharmaceuticals, Inc. (NASDAQ: RETA) securities between October 15, 2019 and August 7, 2020 (the “Class Period”). Investors have until December 14, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Click here to participate in the action.

Reata is a clinical stage biopharmaceutical company that develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.

Among Reata’s drug candidates under development is omaveloxolone, which is in Phase 2 clinical development to treat Friedreich’s ataxia (“FA”). Following the announcement of positive data from the MOXIe Part 2 study of omaveloxolone for FA in October 2019, the Company represented that it would seek submission for marketing approval of omaveloxolone for the treatment of FA in the U.S. with the U.S. Food and Drug Administration (“FDA”).

On August 10, 2020, Reata issued a press release announcing its second quarter 2020 financial results, wherein it disclosed that the FDA is “not convinced that the MOXIe Part 2 results” of the Company’s study assessing omaveloxolone for the treatment of FA “will support a single study approval without additional evidence that lends persuasiveness to the results,” and that, “[i]n preliminary comments for [a] meeting, the FDA stated that [Defendants] will need to conduct a second pivotal trial that confirms the mFARS [modified Friedreich’s Ataxia Rating Scale] results of the MOXIe Part 2 study with a similar magnitude of effect.”

On this news, Reata’s stock price fell $51.79 per share, or 33.16%, to close at $104.41 per share on August 10, 2020.

The Complaint, filed on October 15, 2020, alleges that throughout the Class Period defendants made materially false and misleading statements regarding the Company’s business. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (i) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of FA in the U.S. without additional evidence; (ii) as a result, it was foreseeable that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (iii) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased Reata securities during the Class Period and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker, Melissa Fortunato, or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York and California. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.

Bragar Eagel & Squire, P.C.

Brandon Walker, Esq.

Melissa Fortunato, Esq.

Marion Passmore, Esq.

(212) 355-4648

investigations@bespc.com

www.bespc.com

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Legal Professional Services

MEDIA:

Logo
Logo